WHO ICTRP trial
A study protocol for the treatment of relapsed and refractory B-cell lymphoma of…
ChiCTR2100045519 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2100045519 |
|---|---|
| Public title | A study protocol for the treatment of relapsed and refractory B-cell lymphoma of the central nervous system with abutinib combined with TEDD-R regimen |
| Scientific title | A study protocol for the treatment of relapsed and refractory B-cell lymphoma of the central nervous system with abutinib combined with TEDD-R regimen |
| Primary sponsor | Beijing Boren Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | relapsed and refractory CNS B-cell lymphoma |
| Interventions | Therapy group:Obitinib + chemotherapy (TEDDI-R) regimen |
| Registration date | Apr 18, 2021 |
| Target size | Therapy group:50 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: